• Expected to grow 20-22% in volume for FY 23 and 50% in value terms. Expected revenues for FY 23 would be around 2250 cr.
• Targeting to deliver 5000 cr revenues till FY 27. (Current revenues of 1551 in FY 22).
• Entering in new Speciality Products : Epichlorohydrin and chlorinated pvc. ECH capacity will come in May June of 2022 and CPVC will be online in Q2 2023. Both of these plants needs 3 months to stabilize operations.
• Expanding into chlorotoluenes and it’s value chain. Total capex amount around 180 cr. Asset turnover expected around 2.5 to 3x. It will add 500 cr of revenues.
• Setting up R&D center in ahmedabad for Specialty chemicals.
• Production of hydrogen peroxide has ramped up and capacity utilization is 78% in FY 22 Vs 57% in FY 21.
• Caustic soda and caustic potash realization increased by 74% and 27% respectively.
• Caustic soda realization stood at 34062 in FY 22 vs 21300 FY 21.
• Epichlorohydrin (ECH) project is under commissioning and will get commissioned in next 2 months. Demand for ECH is from construction sector.
• Demand for epoxy resins is around 70000 to 75000 MT and next year it can go upto 85-90 KT
• Meghmani Organics setting up the plant for caustic soda with capacity of 100kt, jinal is also setting up the plant.
• Caustic is not imported in India, it is exported from India. Exports will continue from India for at least next 2 qtrs.
• Capex projects :
1.Epichlorohydrin (ECH)
2.Caustic Soda
3.Chlorinated PVC (CPVC)
• ECH and CPVC are high value products which are derivatives of caustic soda.
• Once in year sizable capacity of caustic soda is needed which can cater to demand from pharma, agrochem, infra, renewable sectors.
• Last year due to lockdown paper and textile industry was not doing well but this year they are performing well. Caustic soda is used in these industries as well.
• Capacity for epichlorohydrin is around 50000 MT. Generally plant needs 2 to 2.5 years to commission.Meghmani finechem commissioning ECH plant this quarter. Epoxy resin is forward integrated derivative of ECH. There are some capacities coming up for epoxy resins also.
It is expected that the growth for ECH will grow in double digits. DCM also coming up with ECH capacity.
• Most of the power requirements fulfilled from captive power plant.
• Looking for import substitute products. New projects not announced yet.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. Introduction
Mayur Uniquoters is primarily engaged in the business of manufacturing and sale of PU (Polyurethane) / PVC (Poly Vinyl Chloride) synthetic leather which is widely used in different segments
such as Footwear, Furnishings, Automotive OEM, Automotive replacement market, and Automotive Exports.
Mayur Uniquoters Ltd is the largest manufacturer of artificial leather, using the 'Release Paper Transfer Coating Technology' in India.
Mayur has the largest installed capacity for manufacturing of synthetic leather in the domestic organized segment with a capacity of 4.05 million linear meters per month (LMPM) of PVC coated fabric having Italian coating lines.
1. Films & TV crossed 100 cr revenues with 15% margin
2. Currently total catalogue of songs stand at 142k vs 130k
3. sarkaru vaari paata and gangubai crossed 1 B views in 3 months
4. Launched 2 marathi movies and 1 web series in this qtr.
5. Management positive about shift from ad-based revenue to premium paid music. Globally this shift already started. In India it's expected in next 12 to 18 months. It it happens saregama will grow at much higher rate
6. Not directly impacted due to netflix. Saregama is content provider and not music/films platform.
7. QIP funds not invested in RPG group companies. Till now acquired Mango music and Issues related expenses utilized from 750 cr. Waiting for deals at good valuations.
1. Revenues for the full year were ₹4936 Cr (3% growth YoY). Gross margin was at 55.6% and EBITDA margin was 29.1%
2. There was significant volatility in the cost of raw materials, solvents and energy. The disruption in the supply chain and logistics has increased mainly
due to the war in Russia and lockdowns in China. This is expected to continue in Q1 and normalization is expected from Q2 onwards.
There is a lot of talk about how Paytm’s business is bad. Let us take a look to see if that is true.
1. Company Overview
Paytm is a payments led super app which allows its customers to access financial and other commercial services through its app. It was founded by
Vijay Shekhar Sharma in 2009 as a prepaid mobile and DTH recharge platform. The company has since evolved to provide multiple fintech services and is one of the largest players in the payments space
Why Netflix down 35%
➡️ Increasing competition
➡️ High valuations
➡️ Lost 2,00,000 customers
➡️ Password sharing 😀
How music labels are different from Netflix ?
➡️ Music labels own the content and monetize it to many platform. Profit pool is concentrated with music lables not at music platforms like spotify
➡️ Indian music labels focusing on regional music which have lot of room to grow
➡️ Music subscription is still very low. It's mostly ad-based revenues. Lot of room available as there will be shift from ad-based to subscription based revenues
➡️ Music is highly repeatable compared to movies.
➡️ Customer don't have to spend anything from pocket to listen music
The US is the largest Healthcare market in the world. Drugs manufactured by Indian pharma companies account for a significant amount of the prescriptions filled in the US. But the big Indian players in the US
market have not been able to drive significant returns for the past few years. Let us try to understand why:
Period of Rapid Growth (FY11-FY17)
During 2010 to 2017, Indian pharma companies saw a boom in the US business. Some of the reasons for this were: